← Search another drug
PatientPulse · by PatientPartner
Lynparza olaparib
High confidence
~53 public patient conversations and reviews referenced across forums, blogs, review sites, and patient-community pages
Executive intelligence
The signal that moves starts & adherence
42%Positive sentiment in discussion
20,092FDA adverse-event reports
91%Flagged serious
78%Reports name female patients
The single highest-leverage commercial moment is the first 4-8 weeks: patients who survive early side effects on a reduced dose become long-term adherents; those who quit early never return.
- Early tolerability is the make-or-break commercial moment: patients who receive proactive dose-reduction guidance in weeks 1-8 stay on therapy long-term, while those who do not often discontinue permanently.
- Cost and insurance access remain a top-of-funnel barrier, especially for Medicare patients, but AstraZeneca copay and patient-assistance programs are widely cited as the practical resolution in the corpus.
- Loss of taste and smell, chronic GI gas, and persistent anemia are under-discussed side effects that drive more quality-of-life distress than the label-prominent nausea narrative suggests to clinicians.
- Long-term users (2 plus years) surface a distinct anxiety about MDS/AML risk and treatment duration limits, creating an adherence paradox where efficacy success paradoxically raises fear of continuing therapy.